前列腺癌筛查19年随访结果:ERSPC鹿特丹试点1队列
该研究评估了ERSPC鹿特丹试点1队列中1991-1992年随机入组的1134名男性,1:1分为筛查组和对照组,筛查组每4年接受PSA检测至74岁,PSA≥3.0ng/ml时行活检。分析时63%男性已死亡,筛查组转移性疾病和前列腺癌死亡的相对风险分别为0.46(95%CI 0.19-1.11)和0.48(95%CI 0.17-1.36)。
要点
- 筛查组转移性疾病相对风险0.46(95%CI 0.19-1.11),方向利于筛查。
- 筛查组前列腺癌死亡相对风险0.48(95%CI 0.17-1.36),方向利于筛查。
- 该队列筛查期间污染少,提示PSA筛查可能大幅降低转移和死亡。
核心结论
- 在污染较少的ERSPC鹿特丹试点1队列中,PSA筛查可能大幅降低转移性疾病和前列腺癌死亡。
研究设计与样本
- ERSPC鹿特丹试点1研究队列,1991-1992年随机入组1134名男性,1:1分为筛查组和对照组,排除PSA≥10.0ng/ml者。
主要发现
- 分析时63%男性已死亡,筛查组转移性疾病相对风险0.46(95%CI 0.19-1.11),前列腺癌死亡相对风险0.48(95%CI 0.17-1.36),均利于筛查。
关键数值与推荐
- 筛查组从55岁起每4年接受PSA检测至74岁,PSA≥3.0ng/ml触发活检。
临床怎么用
- 结果提示PSA筛查可能降低转移和死亡,但需在更大数据集确认后再讨论筛查利弊。
局限性
- 样本量1134名男性,置信区间较宽,需在更大队列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We assessed the effect of screening in the European Randomized study of Screening for Prostate Cancer (ERSPC) Rotterdam pilot 1 study cohort with men randomized in 1991-1992. A total of 1134 men were randomized on a 1:1 basis to a screening (S) and control (C) arm after prostate-specific antigen (PSA) testing (PSA ≥10.0ng/ml was excluded from randomization). Further PSA testing was offered to all men in the S-arm with 4-yr intervals starting at age 55yr and screened up to the age of 74yr. Overall, a PSA level of ≥3.0ng/ml triggered biopsy. At time of analysis, 63% of men had died. Overall relative risk of metastatic (M+) disease and prostate cancer (PCa) death was 0.46 (95% confidence interval [CI]: 0.19-1.11) and 0.48 (95% CI: 0.17-1.36), respectively, in favor of screening. This ERSPC Rotterdam pilot 1 study cohort, screened in a period without noteworthy contamination, shows that PSA-based screening could result in considerable reductions of M+ disease and mortality which if confirmed in larger datasets should trigger further discussion on pros/cons of PCa screening. PATIENT SUMMARY: In a cohort with 19yr of follow-up, we found indications for a more substantial reduction in metastatic disease and cancer-specific mortality in favor of prostate cancer screening than previously reported. If confirmed in larger cohorts, these findings should be considered in the ongoing discussion on harms and benefits of prostate cancer screening.
引用
- Osses DF, Remmers S, Schröder FH, et al. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up. Eur Urol. 2018. PMID: 30420254. doi:10.1016/j.eururo.2018.10.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。